Insider · CIK 0001091823
KIRK RANDAL J
Reports to the SEC for 13 companies · RADFORD, VA
Transactions
50
Companies
13
Filings
4
CIK
0001091823
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$155K |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$78.5K |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$557K |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$129K |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$3.66M |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$168K |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$1.22M |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$502K |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$7.7M |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$168K |
| 2026-03-30 | PGENPRECIGEN, INC.S Sale | −$1.41M |
| 2026-03-13 | PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2026-03-13 | PGENPRECIGEN, INC.M Exercise/Conversion | — |
| 2026-03-10 | PGENPRECIGEN, INC. · Restricted Stock UnitsA Award | — |
| 2026-03-10 | PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award | — |
| 2026-03-10 | PGENPRECIGEN, INC.A Award | +$100K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$394K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$2.32M |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$54K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$4M |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$24.9K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$41.5K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$49.8K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$178K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$666K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$54K |
| 2025-12-22 | PGENPRECIGEN, INC.S Sale | −$162K |
| 2025-11-21 | PGENPRECIGEN, INC.S Sale | −$3.59M |
| 2025-11-20 | PGENPRECIGEN, INC.S Sale | −$3.85M |
| 2025-11-19 | PGENPRECIGEN, INC.S Sale | −$4.86M |
| 2025-09-30 | PGENPRECIGEN, INC.S Sale | −$6.17M |
| 2025-09-19 | PGENPRECIGEN, INC.S Sale | −$13.2M |
| 2025-09-18 | PGENPRECIGEN, INC.S Sale | −$5.42M |
| 2025-09-17 | PGENPRECIGEN, INC. · 8.00% Series A Convertible Perpetual Preferred StockM Exercise/Conversion | — |
| 2025-09-17 | PGENPRECIGEN, INC.M Exercise/Conversion | — |
| 2025-03-14 | PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2025-03-14 | PGENPRECIGEN, INC.M Exercise/Conversion | — |
| 2025-03-13 | PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award | — |
| 2025-03-13 | PGENPRECIGEN, INC. · Restricted Stock UnitsA Award | — |
| 2025-03-13 | PGENPRECIGEN, INC.A Award | +$100K |
| 2024-12-30 | PGENPRECIGEN, INC. · Warrant to Purchase Common StockP Purchase | — |
| 2024-12-30 | PGENPRECIGEN, INC. · 8.00% Series A Convertible Perpetual Preferred StockP Purchase | — |
| 2024-08-09 | PGENPRECIGEN, INC.P Purchase | +$20M |
| 2024-05-02 | PGENPRECIGEN, INC.J Other | — |
| 2024-05-02 | PGENPRECIGEN, INC.J Other | — |
| 2024-05-02 | PGENPRECIGEN, INC.J Other | — |
| 2024-05-02 | PGENPRECIGEN, INC.J Other | — |
| 2024-05-02 | PGENPRECIGEN, INC.J Other | — |
| 2024-05-02 | PGENPRECIGEN, INC.J Other | — |
| 2024-05-02 | PGENPRECIGEN, INC.J Other | — |
Recent filings
- 4KIRK RANDAL J0001213900-26-037443SEC(opens sec.gov)
- 4KIRK RANDAL J0001213900-26-028443SEC(opens sec.gov)
- 4KIRK RANDAL J0001213900-26-027006SEC(opens sec.gov)
- 4KIRK RANDAL J0001213900-25-124794SEC(opens sec.gov)
Companies
- Alaunos Therapeutics, Inc.DirectorTCRT
- AQUABOUNTY TECHNOLOGIES INC10% OwnerAQB
- Armata Pharmaceuticals, Inc.10% OwnerARMP
- CLINICAL DATA INCDirector, 10% Owner
- Fibrocell Science, Inc.10% Owner
- HALOZYME THERAPEUTICS, INC.10% OwnerHALO
- NEW RIVER PHARMACEUTICALS INCDirector, Chairman, President and CEO, 10% Owner
- Ocugen, Inc.10% OwnerOCGN
- ORAGENICS INC10% OwnerOGEN
- PRECIGEN, INC.Director, 10% OwnerPGEN
- Precipio, Inc.10% OwnerPRPO
- SOLIGENIX, INC.10% OwnerSNGX
- Theriva Biologics, Inc.10% OwnerTOVX
Address
C/O THIRD SECURITY, LLC 1881 GROVE AVENUE
RADFORD, VA, 24141